Aptevo surges after cancer patient achieves complete remission in trial

Aptevo Therapeutics

23/11/2021 14:06

** Shares of biotechnology co Aptevo Therapeutics  APVO.O 
surges 89.8% to $12.30 premarket
    ** Co says prelim data shows one high-risk cancer patient
treated with its experimental drug, APVO436, in combination with
chemotherapy achieved complete remission after one cycle of
treatment (https://bit.ly/3xdhrCx)
    ** Complete remission refers to lack of all signs of cancer
in tissue samples removed during surgery or biopsy after
treatment
    ** Prelim data is from early-stage extension study in
patients with acute myeloid leukemia, a type of cancer of blood
and bone marrow with excess immature white blood cells
    ** Trial goal is to determine if APVO436 treatments can
improve quality of remission in patients by reducing the
residual chemotherapy-resistant measurable residual disease
(MRD) or leukemia cells that are present at very low numbers
    ** Co says quality of remission will be assessed in a
centralised lab
    ** Stock down 82.3% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))